Evidence map›Paper›PMID 41309285›Full record

ArticleThorax2026

Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD.

Aparna Balasubramanian, Anna R Hemnes, Evan L Brittain, Jeffrey Annis, Ashraf Fawzy, Nirupama Putcha, Anil Singh, Robert A Wise, Nadia N Hansel, Catherine Simpson and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aparna BalasubramanianDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-1854-6672
Anna R HemnesDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Evan L BrittainDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jeffrey AnnisDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ashraf FawzyDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-6089-366X
Nirupama PutchaDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Anil SinghDivision of Pulmonary and Critical Care Medicine, Alleghany Health Network, Pittsburgh, Pennsylvania, USA.
Robert A WiseDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-8353-2349
Nadia N HanselDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Catherine SimpsonDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Todd M KolbDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Paul M HassounDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Meredith C McCormackDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Stephen C MathaiDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA smathai4@jhmi.edu.

Funding

Early Detection of Right Ventricular Dysfunction and Emerging Pulmonary Hypertension in Systemic SclerosisR01HL162851 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Monica Mukherjee · 2023 to 2026
$2.5M
Pulmonary Vascular Disease as a Contributor to Respiratory Morbidity in Chronic Obstructive Pulmonary DiseaseK23HL153778 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Aparna Balasubramanian · 2022 to 2026
$991k
NHLBI NIH HHS K23 HL153778NHLBI NIH HHS R01 HL162851
6 · The paper itself

Abstract

backgroundCurrent guidelines for the evaluation of chronic obstructive pulmonary disease (COPD) do not recommend screening for pulmonary hypertension (PH), despite the high prevalence and impact on outcomes. A simple screening tool to identify patients with an elevated pulmonary vascular resistance (PVR) is urgently needed, as they may benefit from PH-specific therapy and more urgent referral for lung transplantation. RESEARCH QUESTION: We sought to examine whether a ratio of forced expiratory volume in 1 s (FEV STUDY DESIGN AND

methodsIndividuals with COPD who underwent right heart catheterisation from two academic medical centres were included. Adjusted multinomial models tested associations between FEV

resultsApproximately 40% of the 411 individuals included had PH with an elevated PVR. For every 0.1 increase in the FEV

interpretationThese findings suggest that disproportionate reductions in DLCO predict PH with an elevated PVR in a COPD population. The FEV

Indexed as

Hypertension, PulmonaryPulmonary Diffusing CapacityPulmonary Disease, Chronic ObstructiveVascular ResistanceAgedCardiac CatheterizationFemaleForced Expiratory VolumeHumansMaleMiddle AgedPredictive Value of TestsROC CurveCOPD epidemiologyPulmonary Hypertension

Identifiers

PMID41309285
PMCPMC13098466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.